These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 25623536)

  • 1. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
    Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
    Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting tumor molecular heterogeneity in histopathological diagnosis.
    Mafficini A; Amato E; Fassan M; Simbolo M; Antonello D; Vicentini C; Scardoni M; Bersani S; Gottardi M; Rusev B; Malpeli G; Corbo V; Barbi S; Sikora KO; Lawlor RT; Tortora G; Scarpa A
    PLoS One; 2014; 9(8):e104979. PubMed ID: 25127237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
    Fumagalli D; Gavin PG; Taniyama Y; Kim SI; Choi HJ; Paik S; Pogue-Geile KL
    BMC Cancer; 2010 Mar; 10():101. PubMed ID: 20233444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [KRAS gene mutation in colorectal cancer].
    Roa I; Sánchez T; Majlis A; Schalper K
    Rev Med Chil; 2013 Sep; 141(9):1166-72. PubMed ID: 24522420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
    Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
    Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
    Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
    Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
    Kosmidou V; Oikonomou E; Vlassi M; Avlonitis S; Katseli A; Tsipras I; Mourtzoukou D; Kontogeorgos G; Zografos G; Pintzas A
    Hum Mutat; 2014 Mar; 35(3):329-40. PubMed ID: 24352906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
    Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer].
    Fukushima Y; Yanaka S; Murakami K; Abe Y; Koshizaka T; Hara H; Samejima C; Kishi Y; Kaneda M; Yoshino T
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1825-35. PubMed ID: 22083191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
    Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
    PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.